Insider filing · MNKD

Michael Castagna bought $259K of MannKind (MNKD)

Executed Mar 10, disclosed Mar 11, the same day.

Over the 21 trading sessions from the disclosed entry session (Mar 10), the stock returned -4.0% (delay-adjusted); from the execution session (Mar 10), -4.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

MC Michael Castagna Chief Executive Officer profile →

Michael Castagna (Chief Executive Officer) filed 4 Form 4 reports in the trailing twelve months (1 purchase, 3 sales), most often in MannKind Corporation (MNKD). Across 1 priced purchase filing, the average 21-session return was -4.0% from execution and -4.0% from disclosure (delay-adjusted; derived). The largest single filing was $601K of MNKD (107,920 sh × $5.57, as filed), executed Dec 2 2025.

MNKD MannKind Corporation MNKD · Healthcare · 17 filings in 24 months ticker →

Healthcare · MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→